Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (1390)	7/19/2001 9:22:27 AM
From: Linda Pearson	Read Replies (1) \| Respond to of 1477

Scios Completes Pre-Approval Inspection for Natrecor SUNNYVALE, Calif., July 19 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO) announced today that it has been informed by the San Francisco District Office of the U.S. Food and Drug Administration (FDA) that the Natrecor(R) (nesiritide) pre-approval inspection has been completed. The District Office informed Scios that they will recommend approval of the Natrecor New Drug Application (NDA) to the Center for Drug Evaluation and Research (CDER). CDER is the responsible Center within the FDA for evaluating the Natrecor NDA. Scios has developed Natrecor as an intravenous treatment for patients with acutely decompensated congestive heart failure. Scios also announced that the remaining item to be completed before CDER issues the final action letter on the Natrecor NDA is the finalization of the Natrecor labeling. Discussions with the agency on the final labeling are ongoing. Scios Inc. Scios is a biopharmaceutical company developing novel treatments for cardiovascular and inflammatory disease. The Company's disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and rationally design small molecule compounds for large markets with unmet medical needs. The statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. These include uncertainties associated with the timing of the final approval of Natrecor, as well as other risks detailed from time to time in the reports filed by Scios with the SEC, including the company's annual report on form 10-K for the year ended December 31, 2000 and form 10-Q for the quarter ended March 31, 2001. MAKE YOUR OPINION COUNT - Click Here tbutton.prnewswire.com SOURCE Scios Inc. CO: Scios Inc. ST: California IN: MTC BIO SU: 07/19/2001 08:00 EDT prnewswire.com